// App-Quantinova.ai

: WHAT FACTORS INFLUENCE THE CHOICE OF APIXABAN, RIVAROXABAN, OR DABIGATRAN FOR STROKE PREVENTION AMONG ATRIAL FIBRILLATION PATIENTS IN REAL-WORLD CLINICAL PRACTICE? INSIGHTS FROM THE PROSPECTIVE SPRINT-AF REGISTRY

Researchers

Presenter

  • Andrew C.T. Ha

Principal Investigators

  • Christopher Labos

  • Mahesh Kajil

  • Michelle Tsigoulis

  • Jafna Cox

  • G.B. John Mancini

  • Paul Dorian

  • David Gladstone

  • Evan Lockwood

  • Ashfaq Shuaib

  • William Chan

  • Narendra Singh

  • Milan Gupta

Medical Centers

  • Canadian Collaborative Research Network, Brampton, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved